Telcagepant failure is a headache for Merck (and perhaps Pfizer) but a break for others

While Merck’s latest job cuts were at the fore of its Q2 update (scripintelligence.com, 1 August 2011), the discontinuation of its promising Phase III acute migraine therapy telcagepant is also notable and will add to the company’s woes. It had been expected to become an important treatment option for migraineurs and compete with the triptan class, the standard of care for the past 20 years. Without telcagepant, the acute migraine market will contract, leaving the prophylactic treatment of migraine as the biggest opportunity for developers.

While Merck’s latest job cuts were at the fore of its Q2 update (scripintelligence.com, 1 August 2011), the discontinuation of its promising Phase III acute migraine therapy telcagepant is also notable and will add to the company’s woes. It had been expected to become an important treatment option for migraineurs and compete with the triptan class, the standard of care for the past 20 years. Without telcagepant, the acute migraine market will contract, leaving the prophylactic treatment of migraine as the biggest opportunity for developers.

Merck’s decision to discontinue telcagepant was based on an assessment of data across the clinical program, including findings from a recently completed 6-month Phase III study, according to the company.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By 

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By 

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By 

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

More from Therapeutic Category

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By 

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By 

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By 

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.